Dr. David Alain Wohl is a professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC) and the Institute of Global Health and Infectious Diseases. He is co-Principal Investigator of the Global UNC Infectious Diseases Clinical Research Unit and Site Leader of its Chapel...

“We at the Institute for Global Health and infectious diseases are a large community of multi-disciplinary investigators,” said Sonia Napravnik, PhD, in her webinar welcome message during University Research Week. “And essentially, we all focus on improving health globally and locally, here in North Carolina and across the US.” “Our...

Higher drug levels and combination therapy with low-dose oral methotrexate (LD-MTX) may reduce anti-tumor necrosis factor (TNF) treatment failure in pediatric Crohn’s disease. David Wohl, MD, conducted a post hoc analysis of the COMBINE trial, which compared anti-TNF monotherapy to combination therapy with LD-MTX. The study concluded that the LD-MTX...

North Carolina directly benefits from the work of global health researchers working in other countries, monitoring disease and containing outbreaks. For years, Fischer and David Wohl, MD, have contained diseases like Ebola virus, Marburg virus, Lassa virus, in West Africa, setting up field treatment units during outbreak settings to isolate and effectively care...

Global health issues may seem geographically distant, but they directly impact our local community through travel, immigration, emerging infectious diseases, and interconnected global economies. The ‘global’ in global health refers to the scope of problems, not just their location, which can be infectious diseases with pandemic potention. UNC’s global and...

ID Week took place October 16-19 in Los Angeles, CA, the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. UNC’s Division of Infectious Diseases was...

March is Long COVID Awareness Month, marking four years since COVID-19 was declared a pandemic. But while much of society has moved on from masking, quarantining, and isolating, there are many who are managing health problems long after having COVID-19.  Researchers at the Institute for Global Health and Infectious Diseases are participating in the NIH...

In November 2020, Amy James Loftis was hyper-focused on keeping the Carolina community safe, building UNC’s COVID Surveillance Lab in three short months before the return of students. But there were many years leading up to that moment. Often described as the Institute’s secret weapon in the fight against global...

The UNC Institute for Global Health and Infectious Diseases is now enrolling participants in a fast-track trial of an oral COVID-19 treatment known as Bemnifosbuvir (BEM). Currently, Paxlovid is used for treating COVID-19. However, it is known to interact with common drugs that treat cholesterol, blood clots, and other conditions....

HIV virus eradication is a complex health challenge due to its long-lived persistence and how it hides in latently infected cells that escape the body’s immune system. Effective HIV treatments have decreased the likelihood of someone developing AIDS, while helping individuals live long and healthy lives without transmission to sexual...

This study led by the UNC Institute for Global Health & Infectious Diseases, will enroll 7,500 COVID-positive individuals to answer some of the biggest questions about COVID-19. Investigators explain the study in this video. Over two years into the COVID-19 pandemic and researchers still are looking to answer some of...

As Fischer and Wohl Fight Disease in Sub-Saharan Africa, the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR) Selects UNC to be a Regional Emerging Special Pathogen Treatment Center (RESPTC). Read press announcement. Many courageous infectious disease specialists and other clinicians have not shied...

Survivors of the Ebola outbreak in 2014 report a wide range of lingering symptoms that include fatigue and muscle pain, as well as neurological issues. But not much has been known about the persistence and severity of the symptoms over time. Investigators from the Institute for Global Health & Infectious...

COVID-19 has become a leading cause of death and reduced life expectancy in the U.S., especially among Black and Latino populations. David Wohl, MD, member of the Institute for Global Health & Infectious Diseases and professor of medicine in infectious diseases, and first author Jessie Edwards, PhD, assistant professor in the...

Infectious disease research at the UNC Institute for Global Health and Infectious Diseases (IGHID) attracts unique people driven to make big change in the world. As HIV/AIDS turned 40 in 2021, the world was immersed in a different pandemic, one that brought reminders of the tremendous change science made possible...

  Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and...

Presented by David Wohl, MD, professor of medicine, UNC Division of Infectious Diseases Wohl is site leader of UNC’s Global Infectious Diseases Clinical Research Group at Chapel Hill. For the past year, during the COVID-19 pandemic, Wohl has been serving as medical director of the COVID-19 vaccination clinics at UNC...

  A team of investigators from UNC’s Institute for Global Health and Infectious Diseases has been awarded $1.5 million from the National Institutes of Health to conduct a two-year implementation science study to scale up COVID-19 testing in North Carolina. The researchers will examine the impact of a COVID screening...

ACTG names second new award for former UNC neurology professor, Kevin Robertson The national AIDS Clinical Trials Group expanded its annual recognition program in 2020 with two new awards named for University of North Carolina faculty members who died in 2019: Charles van der Horst, MD, an infectious diseases physician...

  Last week’s authorization by the U.S. Food and Drug Administration for emergency use of bamlanivimab feels like a shot in the arm, so to speak, for David Wohl, MD, a UNC infectious diseases physician and researcher. A monoclonal antibody developed by Eli Lilly to treat mild to moderate COVID-19,...